$1.02 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 133 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADHD | Exit | ALCOBRA LTD | $0 | – | -200 | -100.0% | 0.00% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.03% | – |
| BLRX | Exit | BIOLINERX LTDsponsored adr | $0 | – | -193,284 | -100.0% | -0.04% | – |
| OHRP | Exit | OHR PHARMACEUTICAL INC | $0 | – | -187,500 | -100.0% | -0.05% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -65,538 | -100.0% | -0.07% | – |
| MSTX | Exit | MAST THERAPEUTICS INC | $0 | – | -1,374,900 | -100.0% | -0.07% | – |
| EBIO | Exit | ELEVEN BIOTHERAPEUTICS INC | $0 | – | -87,110 | -100.0% | -0.08% | – |
| JUNO | Exit | JUNO THERAPEUTICS INC | $0 | – | -15,000 | -100.0% | -0.10% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -157,179 | -100.0% | -0.11% | – |
| SGNT | Exit | SAGENT PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.12% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -79,900 | -100.0% | -0.12% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -80,957 | -100.0% | -0.12% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -70,000 | -100.0% | -0.13% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -100,000 | -100.0% | -0.14% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -25,000 | -100.0% | -0.14% | – |
| MDGN | Exit | MEDGENICS INC | $0 | – | -175,000 | -100.0% | -0.15% | – |
| OCRX | Exit | OCERA THERAPEUTICS INC | $0 | – | -321,254 | -100.0% | -0.16% | – |
| Exit | MANNKIND CORPput | $0 | – | -3,000 | -100.0% | -0.16% | – | |
| CNAT | Exit | CONATUS PHARMACEUTICALS INC | $0 | – | -220,000 | -100.0% | -0.16% | – |
| TKAI | Exit | TOKAI PHARMACEUTICALS INC | $0 | – | -146,341 | -100.0% | -0.17% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -50,000 | -100.0% | -0.18% | – |
| THRM | Exit | GENTHERM INC | $0 | – | -34,550 | -100.0% | -0.18% | – |
| UNP | Exit | UNION PAC CORP | $0 | – | -17,489 | -100.0% | -0.20% | – |
| SRCL | Exit | STERICYCLE INC | $0 | – | -14,500 | -100.0% | -0.21% | – |
| PCLN | Exit | PRICELINE GRP INC | $0 | – | -1,820 | -100.0% | -0.22% | – |
| ITB | Exit | ISHARESus home cons etf | $0 | – | -76,000 | -100.0% | -0.22% | – |
| SGMO | Exit | SANGAMO BIOSCIENCES INC | $0 | – | -140,000 | -100.0% | -0.23% | – |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -60,000 | -100.0% | -0.25% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -63,579 | -100.0% | -0.28% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -111,392 | -100.0% | -0.28% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -150,000 | -100.0% | -0.29% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -90,000 | -100.0% | -0.29% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -105,000 | -100.0% | -0.30% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS INC | $0 | – | -230,000 | -100.0% | -0.30% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -75,000 | -100.0% | -0.31% | – |
| AEGR | Exit | AEGERION PHARMACEUTICALS INC | $0 | – | -120,000 | -100.0% | -0.33% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -13,796 | -100.0% | -0.34% | – |
| TJX | Exit | TJX COS INC NEW | $0 | – | -47,330 | -100.0% | -0.34% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -36,000 | -100.0% | -0.35% | – |
| Exit | DYAX CORPput | $0 | – | -2,000 | -100.0% | -0.35% | – | |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -445,000 | -100.0% | -0.38% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.45% | – |
| XLV | Exit | SELECT SECTOR SPDR TRsbi healthcare | $0 | – | -59,853 | -100.0% | -0.45% | – |
| CVS | Exit | CVS HEALTH CORP | $0 | – | -42,260 | -100.0% | -0.45% | – |
| KYTH | Exit | KYTHERA BIOPHARMACEUTICALS I | $0 | – | -90,000 | -100.0% | -0.47% | – |
| KMDA | Exit | KAMADA LTD | $0 | – | -293,727 | -100.0% | -0.54% | – |
| INSYQ | Exit | INSYS THERAPEUTICS INC NEW | $0 | – | -100,000 | -100.0% | -0.60% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -86,637 | -100.0% | -0.62% | – |
| DYAX | Exit | DYAX CORP | $0 | – | -367,556 | -100.0% | -0.64% | – |
| IWM | Exit | ISHARES TRrussell 2000 etf | $0 | – | -56,100 | -100.0% | -0.73% | – |
| ASPX | Exit | AUSPEX PHARMACEUTICALS INC | $0 | – | -125,074 | -100.0% | -1.31% | – |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -210,000 | -100.0% | -1.96% | – |
| B108PS | Exit | ACTAVIS PLC | $0 | – | -192,100 | -100.0% | -5.95% | – |
| Exit | SPDR S&P 500 ETF TRput | $0 | – | -3,500 | -100.0% | -7.52% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.